Cheddar News is watching Moderna as its Stock of the Day after posting fourth-quarter results, which missed estimates.

Closing Bell

Stock Of The Day: Moderna

Time now. For our stock of the day, we're watching shares of Moderna after the pharmaceutical giant posted fourth quarter earnings, This biotech company is starting to see the effects of a waiting pandemic. Its earnings per share were down a whopping 68% from the same period a year ago. It missed Wall Street estimates, sales were also down some 30%. Now it was able to remain solidly profitable. Moderna is dealing with rising costs and the stark reality that the demand for its vaccines well, it's may never recover for those reasons. Its outlook for 2023 is less than rosy. It's expected to take a huge hit to vaccine sales now that americans are shifting to an annual schedule rather than getting boosters every several months. It sold about $18 billion worth of Covid vaccines in 2022. But for 2023 It only has $5 billion 25% in the fourth quarter alone and could keep rising. The biggest expenses for moderna are vaccines that exceed shelf life and that have to be thrown out an unused manufacturing capacity. The U. S. Government is expected to end the National Public Health Emergency as early as May, which means it will stop buying huge orders of these vaccines. So Moderna is gonna have to enter the private market and sell directly to healthcare providers. So a lot of unanswered questions right now for investors, shares in Moderna are down more than 6%. The main question for Moderna is what will be the company's next big money maker After the government stops purchasing its Covid 19 vaccines believe it or not. Moderna's Covid vaccine is its only product currently on the market. It had a number of setbacks in trying to develop new protein based vaccines, including and RNA based flu vaccine that showed mixed results in a recent trial. But the FDA on Wednesday gave Moderna investors hope it designated Moderna and Merck's cancer vaccine as a breakthrough therapy and this means it could be get expedited regulatory review. The personalized vaccine is designed to work in tandem with Merck's keytruda to prevent certain types of cancer and even treat melanoma. Moderna's president says The company is going to present the full results at an upcoming medical conference. Take a look at the Sheraton maternal over the past month, they're down by about 25